07:50 AM EDT, 06/16/2025 (MT Newswires) -- Aquestive Therapeutics ( AQST ) said Monday that the US Food and Drug Administration accepted the company's new drug application for Anaphylm to treat type 1 allergic reactions, including anaphylaxis.

The agency has set a prescription drug user fee act target action date of Jan. 31, the company said.

Aquestive shares were up 7.9% in recent premarket activity.